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Connecting genetic risk to disease end points
through the human blood plasma proteome
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Genome-wide association studies (GWAS) with intermediate phenotypes, like changes in
metabolite and protein levels, provide functional evidence to map disease associations and
translate them into clinical applications. However, although hundreds of genetic variants have
been associated with complex disorders, the underlying molecular pathways often remain
elusive. Associations with intermediate traits are key in establishing functional links between
GWAS-identiﬁed risk-variants and disease end points. Here we describe a GWAS using
a highly multiplexed aptamer-based afﬁnity proteomics platform. We quantify 539 associa-
tions between protein levels and gene variants (pQTLs) in a German cohort and replicate over
half of them in an Arab and Asian cohort. Fifty-ﬁve of the replicated pQTLs are located
in trans. Our associations overlap with 57 genetic risk loci for 42 unique disease end points.
We integrate this information into a genome-proteome network and provide an interactive
web-tool for interrogations. Our results provide a basis for novel approaches to pharma-
ceutical and diagnostic applications.
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G
enome-wide association studies (GWAS) with intermedi-
ate phenotypes, such as metabolite and protein levels,
can reveal variations in protein abundances, enzymatic
activities, interaction properties or regulatory mechanisms, which
can inform clinical applications1–3. Studies with aptamer-,
immunoassay- and mass-spectrometry-based proteomics (Supp-
lementary Table 1) have shown that protein levels are strongly
modulated by variations in the nearby cis regions of their
encoding genes4–9. However, proteomics-based genetic
association studies have been limited by small protein panels
or cohort sizes, and thus, have not systematically addressed
associations across multiple chromosome locations. These trans-
associations are key in establishing functional links between
different risk-variants, because they reveal the downstream
effectors in the pathways between cis-encoded risk-variants and
disease end points.
Here we use a highly multiplexed, aptamer-based, afﬁnity
proteomics platform (SOMAscan)10 in a GWAS to quantify levels
of 1,124 proteins in blood plasma samples. We investigate
samples from 1,000 individuals of the population-based KORA
(Cooperative Health Research in the Region of Augsburg)
study1,11 and replicate the results in 338 participants of the
Qatar Metabolomics Study on Diabetes (QMDiab) with
participants of Arab and Asian ethnicities12.
We identify 539 independent, single-nucleotide polymorphism
(SNP)-protein associations, which include novel inter-
chromosomal (trans) links related to autoimmune disorders,
Alzheimer’s disease, cardiovascular disease, cancer and many
other disease end points. Our study represents the outcome
of over 1,100 new GWAS with blood circulating protein
levels, many of which have never been reported before. We
ﬁnd that up to 60% of the naturally occurring variance in
the blood plasma levels of essential proteins can be explained by
two or more independent variants of a single gene located on
another chromosome, and identify strong genetic associations
with intermediate traits in pathways involved in complex
disorders.
Results
A GWAS with blood circulating protein levels. We used linear
additive genetic regression models, adjusted for relevant
covariates, to analyse 509,946 common autosomal SNPs for
genome-wide associations with 1,124 protein levels measured in
1,000 blood samples from the KORA study (see Methods). We
grouped association signals with correlated SNPs (r240.1) into
single-protein quantitative trait loci (pQTLs) and identiﬁed 539
pQTLs (284 unique proteins, 451 independent SNPs) with a
conservative Bonferroni level of signiﬁcance (Po8.72 10 11
¼ 0.05/509,946/1,124; unless otherwise stated we report
uncorrected P values for the reported traits from linear regression
models). For 21% of the assayed proteins we detected a cis-pQTL
at a more liberal signiﬁcance cutoff of Po5 10 8. The full list
is available as Supplementary Data 1. We then ﬁne-mapped our
associations with variants imputed from the 1,000-Genomes
project database. Next, we attempted replication of 462
associations that had a suitable genotyped tag SNP (r240.8) in
samples from 338 participants of the QMDiab study12. Of those,
234 associations (50.6%) were replicated at a Bonferroni level
of signiﬁcance (Po1.08 10 4¼ 0.05/462), and an additional
150 (totalling to 83.1%) showed nominal signiﬁcance (Po0.05) in
the replication sample. We observed directional consistency
between primary and replication sample for 215 of the
234 replicated SNPs. Discrepancy for the remaining 19 SNPs
may be explained by changes in major and minor allele coding
between the two cohorts and ethnic differences. What is
more, out of 208 associations that had 95% replication
power (determined by sampling), 171 (82.2%) were replicated
and 198 (95.2%) were nominally signiﬁcant. Moreover, we
replicated several associations previously reported in
aptamer-, immunoassay- and mass-spectrometry-based studies,
which demonstrated concordance among these technologies
(Supplementary Tables 1–5).
Interconnectedness and annotation of the plasma proteome.
The SOMAscan aptamers were generated to bind speciﬁcally to
proteins implicated in numerous diseases and physiological
processes and to target a broad range of secreted, intracellular and
extracellular proteins, which are detectable in blood plasma
(Supplementary Fig. 1, Supplementary Data 2). To identify
interrelations between these proteins, we used Gaussian
graphical modelling (GGM) to connect 1,092 proteins through
3,943 Bonferroni-signiﬁcant partial protein–protein correlation
edges (Supplementary Data 3). Then, we added all 451 genetic
pQTL variants as nodes, and connected them to the protein
network through the 539 SNP-protein associations (Fig. 1). This
network is freely available online, and it can be navigated via an
interactive web interface. Overall, we found that given our study
power the blood plasma levels of over 20% of all assayed proteins
were under substantial genetic control, and in some cases,
this control resulted in nearly total protein ablation (Fig. 2).
Additionally, a wide-spread feature was the convergence of
multiple association signals to impact the levels of key proteins of
biomedical and pharmaceutical interest (Supplementary Fig. 2):
with the Ingenuity Pathway Analysis database (IPA, Qiagen Inc.),
we annotated 50 proteins as clinical or pharmaceutical
biomarkers (Supplementary Table 6) and 43 as drug targets
(Supplementary Table 7), and all of these had at least one
replicated pQTL.
Next, we identiﬁed and annotated putative causative and
disease-relevant variants. We used the SNiPA web-tool13
to retrieve variant-speciﬁc annotations for all SNPs from the
1,000-Genomes project that were in linkage disequilibrium with
an identiﬁed pQTL (linkage disequilibrium r240.8). The anno-
tations included primary effect predictions, SNPs in experime-
ntally identiﬁed regulatory elements (ENCODE), expression
QTLs (eQTLs) and disease associated variants. Of
384 annotated cis-pQTLs, 228 had a variant in the gene coding
region, whereof 74 were protein-changing. Eighty-eight had
a variant in a regulatory element, and 179 had an eQTL that
matched the associated protein. We complemented the pQTL
annotation with 122 overlapping methylation QTLs
(meQTLs) (Supplementary Data 1) and 14 overlapping
metabolic QTLs (mQTLs) (Supplementary Table 8). With the
GWAS catalogue as a reference, and by including publicly
available summary statistics data from 16 large disease GWAS
consortia, we identiﬁed 83 GWAS associations for 42 unique
disease end points that overlapped with 57 pQTL loci
(Supplementary Table 9).
Trans-pQTLs link genotype to GWAS end points. Trans-asso-
ciations are exceptionally valuable for identifying new pathways.
These associations establish causal links between proteins encoded
at the GWAS loci and the blood levels of one or several trans-
encoded proteins. We identiﬁed 148 trans-pQTLs and replicated
55. Forty-nine trans-pQTLs had 95% replication power, we repli-
cated 38 of these. Six replicated trans-pQTLs had an additional
replicated cis-association, two had two replicated trans-associations
and one had three replicated trans-associations. Three independent
SNPs at the haptoglobin (HP) locus had together four pQTLs, and
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two proteins had replicated trans-associations at two distinct
chromosome locations (Tables 1 and 2).
In this study, the pleiotropic ABO blood group gene exhibited
the most promiscuous protein association signal. This locus
displayed six independent genetic variants that were associated
with 14 different proteins through replicated trans-pQTLs; three
of these associations had been published previously (VWF, SELE,
SELP, Supplementary Table 2). The other eleven associations
were new, to our knowledge (BCAM, CD200, CD209, CDH5,
FLT4, INSR, KDR, MET, NOTCH1, TEK, TIE1).
Genetic variance in ABO has been associated with coronary
artery disease, stroke14, and diabetes15 (Supplementary Fig. 3).
The non-O blood group is one of the most important genetic risk
factors for venous thromboembolism16, pancreatic cancer17 and
susceptibility to infectious diseases18. However, we lack a full
understanding of the proteins and pathways involved in the
pathogenic effects of these genetic variants. Based on the pQTLs
reported here, we found support for the following three new
hypotheses: First, the association between ABO and levels of
circulating insulin receptor (INSR) reﬂects the previously
reported associations between the ABO locus and diabetes
and the insulin receptor and diabetes15. The association
between ABO and the insulin receptor suggests that INSR-
mediated insulin signalling may be involved in the ABO-diabetes
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Figure 1 | The genome-proteome-disease network. (a) Data sources integrated into the network, indicating the number and type of the overlapping
associations, from the SNP to the disease end point; all associations are freely accessible at http://proteomics.gwas.eu. (b) Circular plot of all cis- and
trans-associations, cis-pQTLs are indicated by triangles, trans-pQTLs connect associated variant locations and trans-encoded protein locations. An
interactive version of this circular plot constitutes an entry point to query the integrated web-server. (c) Example of a genome-proteome-disease
sub-network obtained from the server for a query using the search word ‘Crohn’s Disease’. Network elements are disease traits (pink hexagons), pQTL loci
(green diamonds), protein levels (blue ovals); nodes are connected by genetic associations, partial correlations and disease GWAS associations. This
example (edited here for clarity) revealed four risk loci that associated with plasma levels of C7, MST, IL23R and IL18R, respectively. These four proteins all
have a major role in auto-immune disorders. Partial correlations between neighbouring proteins reveal pathways that may be involved in the aetiology of
Crohn’s disease. Similar networks can be retrieved starting with a query using any of the 539 pQTLs, 1,124 proteins and 42 unique co-associated disease
end points. In the integrated web-server, all items are interactively linked to association data from the discovery and the replication study, regional
association plots based on imputed variants, locus annotations including co-associated eQTL-, meQTL-, mQTL-, regulatory-, coding- and disease
risk-variants, and link-outs to relevant protein databases, original data sources and primary publications. The links in this network reﬂect the outcome of
many natural experiments, represented by genetic variations observed in the genomes of hundreds of individuals from the general population and probed
by deep proteomics phenotyping using over 1,100 different aptamers.
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association. Second, rs651007 associated here with P-selectin
(SELP). SELP-positive platelets were previously reported to be
associated with blood pressure19, and rs651007 was associated
in a GWAS with angiotensin converting enzyme activity. This
variant was further identiﬁed as an mQTL for a number of
dipeptides in blood20, which may be produced by the dipeptidase
angiotensin converting enzyme21. These observations suggest
a potential role for the SELP pQTL in the GWAS association
between ABO and cardiovascular disease. Third, several of the
14 proteins associated here with ABO have been shown to interact
or form complexes in relation with angiogenesis and vascular
maturation processes: The angiopoietin-1 receptor (TEK) has
a role in embryonic vascular development and phosphorylates the
tyrosine kinase TIE1. TIE1 overexpression in endothelial cells
upregulates selectin E (SELE)22. Strain induced angiogenesis is
mediated in part through a Notch-dependent, Ang1/Tie2
signalling pathway that implicates NOTCH1 and TIE1 (ref. 23).
Vascular endothelial (VE)-cadherin (CDH5) is required for
normal development of the vasculature in the embryo and for
angiogenesis in the adult, and it is associated with VE growth
factor (VEGF) receptor-2 (KDR) on the exposure of endothelial
cells to VEGF24. Heterodimers of KDR and vascular endothelial
growth factor receptor 3 (FLT4) positively regulate angiogenic
sprouting25. VEGF directly and negatively regulates tumour cell
invasion through enhanced recruitment of the protein tyrosine
phosphatase 1B (PTP1B) to a hepatocyte growth factor receptor
(MET)—KDR hetero-complex26. VEGF also synergistically
increased tumour necrosis factor-alpha-induced E-selectin
messenger RNA (mRNA) and shedding of soluble E-selectin.
Synergistic upregulation of E-selectin expression by VEGF is
mediated via KDR and calcineurin signalling27. These
observations suggest that genetic variance in ABO has major
effects on a network of proteins involved in cell adhesion,
angiogenesis and neo-vascularization. Consequently, the here
reported trans-pQTLs indicate novel pathways that may
explain ABO-mediated cancer susceptibility through regulation
of vascular metabolism28.
Post-translational modiﬁcations. To follow up on the many
hypotheses generated by the pQTLs reported here, expert
knowledge and experimentation will be required. Given the fact
that several of the proteins identiﬁed in our pQTLs were glyco-
proteins, we performed plasma protein glycoproﬁling (see Online
Methods) to investigate whether some of our pQTLs were
involved in post-translational protein modiﬁcations.
For instance, SNP rs3760775, located at the FUT3 gene locus,
was associated with plasma levels of the there encoded galacto-
side3(4)-L-fucosyltransferase protein. We found that this same
variant was strongly associated with the N-glycan GP33 (P¼ 1.4
 10 15) (see Fig. 3a for the GP33 glycan structure). In a
previous GWAS, SNP rs3760775 was reported to be associated
with the glycan antigen, CA19-9 (ref. 29), a widely used cancer
biomarker, which is present on multiple proteins30. Nearly
20 years ago, studies demonstrated a similar association between
CA19-9 and the FUT3 gene dosage31,32. This previously reported
association between variance in the FUT3 locus and the
expression of cancer antigen, CA19-9, and our observation
of a similar association with GP33, suggest that both glycans may
be involved in a same pathway.
Another glycoproﬁle investigation began with the strong,
genotype-dependent correlation between complement factor
C4 and the N-glycan, GP19 (P¼ 2.0 10 27) (Fig. 3d). We
found that SNP rs8283 was associated with both C4 and GP19.
GP19 is composed of nine mannose moieties (M9 glycan
structure), and it was previously reported to be attached to
C4 (ref. 33). Moreover, M9 glycans are the principal target ligand
for mannose-binding protein (MBL), which binds to C4 (ref. 34),
and subsequently, activates the complement system through the
lectin pathway. MBL has been implicated in the pathology of
rheumatoid arthritis in many studies, including a recent meta-
analysis, which conﬁrmed the association between functional
MBL variants and rheumatoid arthritis risk35. The rs8283 variant
was also associated with rheumatoid arthritis (P¼ 3.8 10 51)
(ref. 36), but is not in linkage disequilibrium with the top
reported rheumatoid arthritis-risk variants in the HLA region.
Hence, SNP rs8283 appears to be an independent signal, possibly
mediated through MBL binding to C4 glycans.
Biomedical relevance. A major challenge in conducting a disease
GWAS is the difﬁculty in identifying causative variants in
the pathophysiological pathways that lead to the observed clinical
manifestations. Generally, hypotheses about the identity of
the disease-causing genes are based on biological arguments,
such as the presence of SNPs in the regulatory or coding
regions of functionally plausible genes, which may be supported
by co-associated eQTLs. However, a much stronger argument
is provided by the co-association with a pQTL, which
constitutes ﬁrm experimental evidence that the blood levels of
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Figure 2 | Examples of protein levels that are determined by multiple
independent genetic variants. Box-whisker plots of protein levels of
(a) Haemopexin HPX and (b) SLAMF7 as a function of genotype. Data
presented from the KORA study (N¼ 997). Whiskers extend to the most
extreme data point that still falls within the 1.5 inter-quartile range. The
number of minor alleles of the respective genetic variant is given; for
instance, in a, ‘002’ refers to individuals that are homozygous for the major
alleles of rs61818956 and rs4915318 and for the minor allele of
rs10494745, and in b, ‘0.2’ refers to homozygotes of the major allele of
rs11581248 and the minor allele of rs489286. Only variant combinations
that were observed in the study population are shown in the case of HPX.
SNPs rs61818956, rs4915318 and rs10494745 are located in trans in the
CFHR2/CFHR4 gene locus. Further examples are shown in Supplementary
Fig. 2.
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Table 1 | List of replicated trans-pQTLs.
Locus Candidate cis-gene(s) Sentinel
SNP
Chr Position Type Pvalue
KORA
P value
QMDiab
Protein name (gene symbol)
192 GJA9ace, RHBDL2ace, RP5-
864K19.6ace, RRAGCab,
MYCBPac,y
rs4494114 1 39,339,682 Trans 1.9 10 20 3.0 10 8 Kunitz-type protease inhibitor 1
(SPINT1)
210 C1orf168bc, C8Aa, C8Ba, DAB1b rs626457 1 57,407,484 Trans 3.3 10 19 1.7 108 Neurexophilin-1 (NXPH1)
71 PSRC1ac, CELSR2ac, AMPD2b,
SORT1c
rs646776 1 109,818,530 Trans 1.0 10 52 1.7 10 18 Granulins (GRN)
413 F5ae rs9332653 1 169,490,772 Cis 1.6 10 11 7.5 10 5 Coagulation Factor V (F5)
Trans 1.9 10 11 1.5 10 5 Calcium/calmodulin-dependent
protein kinase type 1 (CAMK1)
17 F5ae, SELPb, SELLb rs4525 1 169,511,734 Trans 2.0 10 110 1.3 10 32 Calcium/calmodulin-dependent
protein kinase type 1 (CAMK1)
98 CFHa, CFHR3c rs6695321 1 196,675,861 Trans 9.4 10-40 5.1 10 5 Complement C1s subcomponent
(C1S)
72 CFHR4ae, CFHR2a, ASPMa,
ZBTB41a
rs10494745 1 196,887,457 Trans 1.8 10 52 2.4 10 11 Haemopexin (HPX)
76 CFHR4ac, CFHR2/5a,CFHR1/3c,
CFHc
rs10801582 1 196,944,357 Trans 1.1 1049 2.0 10 11 Haemopexin (HPX)
122 TRIM58ae rs1339847 1 248,039,294 Trans 9.2 10 33 5.4 10 6 Dynein light chain roadblock-type 1
(DYNLRB1)
93 COLEC11ac, ALLCc rs7588285 2 3,648,186 Cis 1.1 1040 1.4 10 16 Collectin-11 (COLEC11)
Trans 2.7 10 37 8.7 10 20 Interleukin-19 (IL19)
157 LTFabe, CCR5b, CCR3c rs1126478 3 46,501,213 Trans 5.1 10 26 4.1 10 13 Alkaline phosphatase, tissue-
nonspeciﬁc isozyme (ALPL)
95 IP6K2abce, CELSR3abc,
NCKIPSDabc, ARIH2abc,
USP19abe,...
rs11715835 3 48,770,732 Trans 2.2 1040 4.2 10 8 Thioredoxin domain-containing
protein 12 (TXNDC12)
91 RBM6ac, RNF123ae, BSNa,
AMIGO3a, GMPPBa,...
rs4688759 3 50,008,118 Trans 1.8 1042 4.2 10 8 Thioredoxin domain-containing
protein 12 (TXNDC12)
52 DCBLD2c, CPOXc, ST3GAL6c rs10935480 3 98,431,986 Trans 9.9 10 70 1.2 10 17 Vascular endothelial growth factor
receptor 3 (FLT4)
352 DNAJC13abc, ACAD11abe,
NPHP3ac, ACKR4a, UBA5a,...
rs17412738 3 132,257,419 Trans 5.3 10 13 3.8 10 5 C-C motif chemokine 21 (CCL21)
203 PCOLCE2ac, U2SURPb, ATRb,
PLS1b
rs4683702 3 142,617,138 Trans 2.0 10 19 8.3 10 5 Endothelin-converting enzyme 1
(ECE1)
31 HRGae rs2228243 3 186,395,113 Cis 4.7 1094 2.7 10 25 Histidine-rich glycoprotein (HRG)
Trans 4.2 1082 6.0 10 18 Dual speciﬁcity mitogen-activated
protein kinase kinase 4 (MAP2K4)
43 HRGae rs1042445 3 186,395,436 Trans 8.4 10 78 1.2 10 22 Dual speciﬁcity mitogen-activated
protein kinase kinase 4 (MAP2K4)
26 KNG1ae rs2304456 3 186,445,052 Cis 2.9 1097 2.8 1040 Kininogen-1 (KNG1)
Trans 1.4 10 10 1.5 106 Leucine carboxyl methyltransferase
1 (LCMT1)
96 KNG1ae rs5030062 3 186,454,180 Trans 3.0 1040 1.7 10 13 Coagulation Factor XI (F11)
Trans 1.8 10 35 8.0 10 10 Plasma kallikrein (KLKB1)
123 SKIV2Lac, C2a, NELFEa, DXOa,
STK19a,...
rs9283893 6 31,897,219 Trans 1.2 10 32 1.6 10 28 Neutrophil collagenase (MMP8)
159 SKIV2Lace, C4Bac, TNXBab,
DXOa, STK19a,...
rs387608 6 31,941,557 Trans 2.5 10 25 2.4 10 8 gp41 C34 peptide, HIV
(Human-virus)
182 TAP2a, PSMB9a, TAP1a,
PSMB8a, COL11A2b,...
rs17220241 6 32,822,244 Trans 9.6 10 22 1.3 10 5 Alpha-2-macroglobulin receptor-
associated protein (LRPAP1)
417 ZFPM2a, CXCL5d rs16873418 8 106,592,145 Trans 1.9 10 11 1.5 10 5 Tumour necrosis factor receptor
superfamily member EDAR (EDAR)
442 ABOac, SURF1c, SLC2A6c,
GBGT1c
rs7857390 9 136,128,546 Trans 5.8 10 11 1.0 106 Tyrosine-protein kinase receptor
Tie-1, soluble (TIE1)
69 ABOabce, OBP2Bbc, DBHb,
SURF1/2b, ADAMTSL2b,...
rs8176749 9 136,131,188 Trans 6.1 10 53 2.7 1042 Cadherin-5 (CDH5)
Trans 1.7 10 51 3.5 10 27 Tyrosine-protein kinase receptor
Tie-1, soluble (TIE1)
Trans 1.1 10 35 2.0 10 10 Angiopoietin-1 receptor, soluble
(TEK)
Trans 1.5 10 11 5.8 10 5 Basal cell adhesion molecule
(BCAM)
Cis* 6.0 10 10 5.3 10 6 Neurogenic locus notch homolog
protein 1 (NOTCH1)
354 ABOac, SURF6c rs8176720 9 136,132,873 Trans 7.4 10 10 6.8 108 Insulin receptor (INSR)
Please see the legend of Table 2 for a description of the replicated trans-pQTL loci.
*NOTCH1 is encoded in cis on chromosome 9, but distant from ABO.
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disease-associated proteins vary in response to changes in the
genome. Moreover, partial correlations to functionally related
proteins, as reported here, may further substantiate and extend
hypotheses generated from pQTLs (see example in Fig. 1c). In the
following sections, we show how pQTLs identiﬁed in this study
reveal new insights into multiple disease-associated pathways
identiﬁed in previous GWAS.
Auto-immune disorders. Ankylosing spondylitis is a common
cause of inﬂammatory arthritis and affects one in 200 Europeans.
Evans et al.37 identiﬁed two independent ankylosing spondylitis-
risk variants in the endoplasmic reticulum aminopeptidase 1
(ERAP1) gene; they reported that the major allele of rs30187 and
the minor allele of rs10050860 were protective. ERAP1 is involved
in trimming peptides before HLA class I presentation. It has
recently attracted attention as a drug target for auto-immune
disorders38. Several studies showed that ERAP1 was present in
blood, localized to exosome-like vesicles and present in the
extracellular space39. Here we found that the two previously
identiﬁed ankylosing spondylitis-risk variants were associated,
Table 2 | List of replicated trans-pQTLs
Locus Candidate cis-gene(s) Sentinel
SNP
Chr Position Type Pvalue
KORA
P value
QMDiab
Protein name (gene symbol)
36 ABOabc, TSC1b, AK8b, SARDHb,
GBGT1c
rs505922 9 136,149,229 Trans 1.2 10 20 1.0 10 8 von Willebrand factor (VWF)
Trans 7.6 10 86 4.1 10 28 CD209 antigen (CD209)
269 ABOac, DBHb, ADAMTSL2b,
SARDHb, RALGDSb,...
rs630510 9 136,149,581 Trans 1.6 10 15 2.4 10 10 Tyrosine-protein kinase receptor
Tie-1, soluble (TIE1)
28 ABOac, DBHb, ADAMTSL2b,
SARDHb, RALGDSb,...
rs651007 9 136,153,875 Trans 1.2 10 96 8.2 10 23 E-Selectin (SELE)
Trans 3.9 1044 5.2 10 15 Insulin receptor (INSR)
Trans 1.1 10 31 1.4 108 Vascular endothelial growth factor
receptor 3 (FLT4)
Trans 3.3 10 19 1.2 109 Hepatocyte growth factor receptor
(MET)
Trans 3.1 10 13 1.9 10 5 Vascular endothelial growth factor
receptor 2 (KDR)
Trans 7.4 10 13 3.4 10 6 P-Selectin (SELP)
Trans 8.0 10 11 8.2 106 OX-2 membrane glycoprotein
(CD200)
79 CPN1a, HIF1ANc rs7091871 10 101,810,304 Trans 1.0 1048 3.5 10 16 Calcium/calmodulin-dependent
protein kinase type 1 (CAMK1)
Trans 1.4 10 12 1.7 10 7 Calpastatin (CAST)
150 SIK3ab, SIDT2bc, PCSK7b,
BUD13b, RNF214b,...
rs12099358 11 116,726,048 Trans 1.6 10 26 1.9 108 Beta-endorphin (POMC)
65 OAFabe, POU2F3bc, ARHGEF12b,
TMEM136b, TRIM29b,...
rs692804 11 120,099,368 Trans 1.1 10 56 5.3 10 24 Interleukin-25 (IL25)
115 C1Sabce, C1RLc rs12146727 12 7,170,336 Cis 3.4 10 35 3.6 10 7 Complement C1r subcomponent
(C1R)
Trans 2.0 10 15 8.8 10 6 Complement C1q subcomponent
(C1QA C1QB C1QC)
304 POC1B-GALNT4ace,
GALNT4ace, POC1Bac, ATP2B1c
rs722414 12 89,937,437 Trans 2.3 10 14 3.1 10 6 CMRF35-like molecule 6 (CD300C)
8 ZC3H13ae, CPB2ae, LCP1c rs1926447 13 46,629,944 Trans 2.2 10 145 4.3 10 5 MAP kinase-activated protein
kinase 3 (MAPKAPK3)
155 PROZac, PCID2a, CUL4Aa rs515863 13 113,839,747 Trans 2.5 10 26 6.2 109 Dual speciﬁcity mitogen-activated
protein kinase kinase 2 (MAP2K2)
67 DHX38ac, TXNL4Ba, PMFBP1a,
HPRc, DHODHc, HPc
rs9302635 16 72,144,174 Cis 6.3 10 54 6.2 10 19 Haptoglobin (HP)
Trans 2.8 10 10 1.4 108 Ferritin (FTH1 FTL)
82 SARM1ac, VTNa, SLC46A1a,
TMEM199c, POLDIP2c,
TMEM97c
rs2239908 17 26,725,265 Trans 9.5 1048 3.1 10 10 Semaphorin-3A (SEMA3A)
Trans 3.0 10 24 3.9 10 8 Calcium/calmodulin-dependent
protein kinase type 1D (CAMK1D)
Trans 1.1 10 10 7.7 10 5 WNT1-inducible-signalling pathway
protein 1 (WISP1)
54 APOC4ae, APOC4-APOC2ae,
APOC2a, APOEc, APOC1c,...
rs5167 19 45,448,465 Trans 2.1 10 69 9.5 106 Granulocyte colony-stimulating
factor (CSF3)
106 TRPC4APabc, EDEM2abc,
PROCRace, GSSab, MYH7Bab,...
rs867186 20 33,764,554 Trans 5.5 10 38 9.0 10 24 Vitamin K-dependent protein C
(PROC)
Loci that comprise at least one replicated trans-association. Loci are referenced in this study by numbers ranging from 1 to 451 (strongest to weakest) and sorted here by chromosome position. P values
are for the association with inverse-normal scaled protein levels from linear regression with genotype; see Supplementary Data 1 for full data of all 539 SNP-protein associations at 451 loci, including
statistics for association with alternatively raw- and log-normal-scaled protein levels and estimated replication power. Candidate genes for the protein associations were annotated by considering the
following criteria: a variant in linkage disequilibrium with the sentinel SNP (r240.8) is located in the gene transcript (superscript a), a variant hits a regulatory element of that gene (superscript b), a
variant is a cis-eQTL (superscript c), a variant is a trans-eQTL (superscript d), a variant is protein changing (superscript e). The list of candidate genes in this table is limited to the ﬁve most plausible
candidate genes for each locus. The full list is available online and in Supplementary Data 1. Every trans-pQTL implies the existence of a functional and causal link between a cis-encoded candidate gene
and the trans-encoded target protein(s).
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in an additive manner, with increasing levels of circulating
ERAP1 protein (Fig. 4a). Similarly, mRNA sequences isolated
from lymphoblastoid cells showed that ERAP1 mRNA expression
also increased with increasing numbers of ankylosing
spondylitis-risk alleles (Fig. 4b). Previous work concluded that
the association between ERAP1 and ankylosing spondylitis was
mainly driven by genetic differences in how ERAP1 enzymatic
activity shaped the HLA-B27 peptidome40,41. However, our
ﬁndings suggest that the auto-immunogenic effects of different
ERAP1 protein variants may in addition be modulated by
genotype-dependent regulation of protein expression. This
observation may have broader implications for treatment
approaches to autoimmune disorders that depend on ERAP1
antigen processing.
Complement system and haem clearance. We identiﬁed two
independent variants (rs10494745 and rs10801582), located in the
complement factor H-related 2/4 (CFHR2/CFHR4) gene locus.
These variants were associated in trans with haemopexin (HPX)
protein levels (Fig. 2a). Lower CFHR4 expression levels were
associated with lower HPX protein levels. HPX binds haem with
high afﬁnity and transports it from the plasma to the liver, which
prevents the accumulation of oxidative species. The rs10494745
variant is a G-E amino acid substitution in CFHR4. It is an eQTL
for CFHR4 expression in liver, as it tags the GTEx rs4915318
variant (GTEx, P¼ 1.6 10 7). Imputed data revealed a third,
strong, and independent signal on SNP rs61818956 (P¼ 1.13
 10 74), which is located in an intron in the CFHR2/CFHR4
locus. Conditional analysis showed that all three variants were
statistically independent, and together, they explained a surprising
61% of the observed variance in a key protein responsible for
oxidative stress reduction. Previous studies reported that CFHR4
interacts with complement component 3 (C3) (ref. 42), and in
turn, C3 interacts with haem43. Those ﬁndings suggest a plausible
trans-acting pathway that links CFHR4 and HPX. That
observation may have important consequences on our
understanding of the pathologies involving the classical and
alternative complement activation pathways.
Alzheimer’s disease (AD) and mRNA splicing. Our ﬁndings on
the major AD-risk variant, rs4420638, may generate particular
medical interest. This variant displayed a cis-association with
increased levels of apolipoprotein E (isoform E2) (APOE) and
a concordant trans-association with decreased levels of small
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Figure 3 | Genotype-dependent co-associations of the plasma proteome and the plasma N-glycome. Bee swarm plots of total plasma N-glycans GP19
and GP33 (% of total N-glycan content) as a function of rs3760775 and rs8283 genotype, respectively, see inset for glycan structure, Blue squares:
N-acetylglucosamine, green circles: mannose, yellow circles: galactose, purple diamonds: N-acetylneuraminic acid; Scatter plots of total plasma N-glycans
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nuclear ribonucleoprotein F (SNRPF aka RUXF). This dual
association was further supported by the ﬁnding that the ratio
between APOE and SNRPF strengthened the association with
rs4420638 by 16 orders of magnitude (p-gain statistic44).
Although this association lacked sufﬁcient replication power,
both APOE and SNRPF associations remained nominally
signiﬁcant in the QMDiab cohort (Po0.012), with concordant
trends. SNRPF is a core component of U1, U2, U4 and U5 small
nuclear ribonucleoproteins, which are the building blocks of the
spliceosome. Recently, a knock-down of U1-70K or inhibition of
U1 small nuclear ribonucleoprotein components was shown to
increase the levels of amyloid precursor protein45. An association
between this major AD-risk variant and a protein of the
spliceosomal machinery has not been reported previously.
Taken together, these observations support the implication that
protein splicing may be an important factor in AD. Furthermore,
the trans-association between SNP rs4420638 and SNRPF had
opposite directionality compared with that with APOE levels.
These observations suggest that a regulatory mediator is most
likely involved. Theoretically, pharmacological targeting of this
mediator could cause an increase in SNRPF, which would
increase splicing, and potentially decrease amyloid precursor
protein levels.
Pharmacogenetics. A pQTL that implicates a drug target may
affect patient response to treatment. For example, we observed a
strong, replicated cis-association between rs489286 and reduced
blood levels of the signalling lymphocytic activation molecule-F7
(SLAMF7) in carriers of the minor allele. This was further
conﬁrmed with a SLAMF7-eQTL that showed identical direction-
ality in mRNA sequencing data from lymphoblastoid cell lines
(Supplementary Fig. 4). Furthermore, imputed data identiﬁed
a strong association between SLAMF7 protein levels and a SNP in
the SLAMF7 intron, rs11581248; heterozygous alleles caused
severely reduced SLAMF7 levels, and the homozygous minor allele
nearly ablated the SLAMF7 protein (Fig. 2). SLAMF7 is targeted by
the recently FDA-approved cancer drug, Elotuzumab, a humanized
monoclonal antibody prescribed for relapsed or refractory multiple
myeloma. Previously, a small study on Japanese women indicated
an association between rs17313034 (r2¼ 0.82 with rs489286) and
cervical cancer46; it showed that the minor allele had a protective
effect. Taken together, these data suggest the possibility that the
response to Elotuzumab treatment may depend on the patient’s
rs489286 genotype, and that homozygotes of the rarer rs11581248
variant (1.5% of the population) may not respond to Elotuzumab.
We cannot exclude the possibility that rs17313034 affects the
SLAMF7 epitope, which could potentially alter SLAMF7-aptamer
binding. However, such an alteration might then also affect
Elotuzumab binding. This hypothesis can be tested retrospectively
in the phase-3 clinical trial cohort47.
Drug target validation. Plenge et al.48 suggested that naturally
occurring genetic variance could be used to validate drug targets,
based on genotype–phenotype dose–response curves. For
example, IL6R was previously proposed as a target for
preventing coronary heart disease. Recently, tocilizumab,
a humanized antibody that targets IL6R, was developed and is
currently approved for treating rheumatoid arthritis.
Plenge et al.48 required that, for validating drug targets, the
gene must include multiple causative variants of known biological
function. A large IL6R Mendelian randomization analysis49
found that SNP rs7529229 was associated with increased IL6R,
reduced CRP, reduced ﬁbrinogen, and reduced odds of coronary
heart disease (P¼ 1.53 10 5). The CardiogramPlus consortium
GWAS data conﬁrmed that association (P¼ 1.66 10 8). In the
present study, we replicated the IL6R-pQTL (rs4129267, r2¼ 0.94
with rs7529229). Furthermore, we identiﬁed a second SNP in
IL6R, rs11804305, which tags an independent and causative
variant, since rs4129267 was already established as functional.
Therefore, these two SNPs could be used to investigate dose–
response curves in the huge data set available from the IL6R-
Mendelian randomization consortium49. A similar approach is
now feasible for all other protein drug targets that were associated
here with multiple pQTLs (for examples see Supplementary
Fig. 2). What is more, the aptamers that were used in this study to
target these proteins can readily be used as intermediate readouts
in assessing drug responses and in optimizing the efﬁcacy of lead
components.
Application to disease GWAS. Genetic associations with inter-
mediate traits are generally much stronger than associations with
disease end points, due to their proximity to the causative variant,
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as shown in our previous GWAS with metabolic traits50.
Therefore, pQTLs can serve as proxies to ﬁne-map genetic
disease associations. This approach can be used to identify
potentially causative genes and additional independent
genetic signals at a locus identiﬁed in a disease-GWAS. In
particular, pQTLs can be used to identify true positive
associations among associations that do not reach genome-wide
signiﬁcance. For instance, rs12146727 was associated with
cardiovascular disease (CVD; P¼ 6.18 10 5) in Cardio-
gramPlus and with AD (P¼ 3.10 10 5 in the discovery
cohort (st1), and P¼ 8.27 10 6 in a combined analysis of a
larger cohort (st12comb)) in the International Genomics of
Alzheimer’s Project. A true positive association requires that the
association signal must be strengthened with increasing sample
numbers, which was the case for the st1 and st12comb cohorts. In
the present study, rs12146727 was replicated as a cis-pQTL for
complement C1r subcomponent (C1R), and it was replicated as a
trans-pQTL for complement C1q subcomponent (C1QA/C1QB/
C1QC). These associations support growing evidence that
suggests that the complement system has a role in both,
AD and CVD51. This example also shows how variants that
associate with a disease end point could generate new hypotheses
about the role of the co-associated proteins in the disease
aetiology. Note that even when these variants have small effect
sizes or odds ratios, the related pathways may show large
responses to pharmaceutical alteration of these proteins.
Hypotheses generated with this approach can be directly tested
in animal models, and the existing aptamers can be potentially
used as intermediate functional readouts in the drug development
process.
Discussion
Genetic studies with yeast52 and lymphoblastoid cell lines53–55
have indicated that cellular protein levels are under strong genetic
control. This control was conﬁrmed by the discovery of many
cis-acting genetic variants in the human blood proteome4–9. Here
we described the ﬁrst large-scale proteomics GWAS on blood
plasma proteins derived from a human population. This GWAS
represented over 1.1 million individual aptamer binding
experiments. By design, our panel of more than 1,100 aptamer
targets was highly enriched in biomedically relevant blood
circulating proteins, which was reﬂected in the large overlap
of pQTLs with risk loci identiﬁed in disease-GWAS. The
data generated from this study can be used in future
investigations to identify and validate causative variants
identiﬁed in disease GWAS. For instance, aptamer-based read-
outs can be used as intermediate traits in CrispR-based
experiments, as exempliﬁed with the FTO-obesity association
described by Claussnitzer et al.56,57.
Surprisingly, we found that up to 60% of the naturally
occurring variance in the blood plasma levels of essential
proteins could be explained by two or more independent
variants of a single gene located on another chromosome
(trans-associations). We identiﬁed strong genetic associations
with intermediate, and most likely functional, traits related to
proteins involved in complex disorders. While many of our
associations connect these proteins to disease pathways through
shared associations, it should be borne in mind that confounding
is always a possibility and needs to be ruled out by further
experimentation. Our data can be used in future studies to
establish dose-response curves for drug-target validation48.
A greater understanding of the genetic control of circulating
levels of protein drug targets and biomarkers may improve
pharmaceutical interventions and clinical trials. Because all the
aptamers used in this study were synthetically generated and
are well deﬁned, they can be readily developed into speciﬁc assays
for precise clinical applications. For instance, the SLAMF7-
binding aptamer identiﬁed here, which revealed a potential
genetic effect on Elotuzumab, may be developed directly into
a clinical assay for identifying differential responders
to immunotherapy. Moreover, this concept can be generalized
to other drug targets and biomarkers.
Despite the variable baseline conditions among the participants
of the replication cohort (not fasting, high prevalence of diabetes
and multiple ethnic backgrounds), we replicated 82% of all
sufﬁciently powered associations. This result emphasized the
robustness of the replicated associations. It also suggests that
many of the Bonferroni-signiﬁcant associations that could not
be replicated in our QMDiab cohort may be replicated in
future studies. About 20% of all assayed proteins had a signiﬁcant
pQTL association. This number is expected to increase in future
more highly powered studies.
Genetic variance in a protein sequence may affect its
higher order structure, and thus, its aptamer-binding afﬁnity.
Similarly, alterations in protein structure may affect binding
and speciﬁcity in immunoassay-based methods and protein mass
in targeted mass spectrometry (MS)-based methods. These issues
remain to be addressed. In this study, we showed that structural-
based epitope effects on a particular pQTL may be identiﬁed or
ruled out in several ways, including: allele-speciﬁc transcription
analysis (for example, CPNE1, Supplementary Fig. 5),
co-associated eQTLs, particularly when they include multiple
genetic variants (for example, ERAP1, Fig. 4), the absence of
correlated SNPs that alter the protein structure (for example,
based on SNiPA-annotated 1000 Genomes data), and replication
on different platforms (Supplementary Tables 2, 4 and 5). We did
not directly follow up on our results using mass spectroscopy.
However, Ngo et al.58 recently showed that response curves for
selected aptamer-enriched proteins were linear over a wide
dynamic range of spiked protein concentrations. Most
importantly, trans-associations, which were a central focus of
this study, are not affected by this type of potential artefact.
In summary, our GWAS demonstrated the power of linking
the genome to disease end points via the blood proteome. As we
have shown in the examples, mining of our data can reveal
a plethora of new insights into biological processes and provide a
wealth of functional information that is beyond the focus
of a single publication. Therefore, we have provided additional
interpretations of selected loci in Supplementary Note 1.
Furthermore, our complete results are freely accessible for
further analyses of pQTL associations with past and
future disease GWAS, on an integrated web-server at
http://proteomics.gwas.eu.
Methods
Study population. The KORA F4 study is a population-based cohort of
3,080 subjects living in southern Germany. Study participants were recruited
between 2006 and 2008 comprising individuals who, at that time, were aged
32–81 years. KORA F4 is the follow-up study of the KORA S4 survey conducted in
1999–2001 (4,261 participants). The study design, standardized sampling methods
and data collection (medical history, questionnaires, anthropometric measure-
ments) have been described in detail elsewhere (ref. 11 and references therein). For
this study, 1,000 individuals were randomly selected from a subset of 1,800 already
deeply phenotyped KORA F4 study participants1,59,60. All study participants have
given written informed consent and the study was approved by the Ethics
Committee of the Bavarian Medical Association.
The QMDiab is a cross-sectional case-control study that was conducted
between February and June 2012 at the Dermatology Department of HMC in
Doha, Qatar. QMDiab has been described previously and comprises male and
female participants in near equal proportions, aged between 23 and 71 years,
mainly from Arab, South Asian and Filipino descent12. The initial study was
approved by the Institutional Review Boards of HMC and Weill Cornell
Medicine—Qatar (WCM-Q) (research protocol #11131/11). Written informed
consent was obtained from all participants.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14357 ARTICLE
NATURE COMMUNICATIONS | 8:14357 | DOI: 10.1038/ncomms14357 | www.nature.com/naturecommunications 9
Blood sampling. Blood samples for omics-analyses and DNA extraction were
collected between 2006 and 2008 as part of the KORA F4 follow-up. To avoid
variation due to circadian rhythm, blood was drawn in the morning between
08:00 and 10:30 after a period of at least 10 h overnight fasting. Blood was collected
without stasis and was kept at 4 C until centrifugation. The material was then
centrifuged for 10min (2,750g at 15 C). Plasma samples were aliquoted and stored
at  80 C until assayed on the SOMAscan platform. For QMDiab, non-fasting
plasma specimens were collected in the afternoon, after the general operating hours
of the morning clinic, and processed using standardized protocols. Cases and
controls were collected as they became available, in a random pattern and at the
same location using identical protocols, instruments and study personnel. Samples
from cases and controls were processed in the lab blinded to their identity. After
collection, the samples were stored on ice for transportation to WCM-Q. Within
six hours after sample collection all samples were centrifuged at 2,500g for 10min,
aliquoted, and stored at -80 C until analysis.
Genotyping. The Affymetrix Axiom Array was used to genotype 3,788 partici-
pants of the KORA S4 study. After thorough quality control (total genotyping rate
in the remaining SNPs was 99.8%) and ﬁltering for minor allele frequency 41%,
a total of 509,946 autosomal SNPs was kept for the GWAS analysis. One-thousand
Genomes Project-imputed genotypes were used for ﬁne mapping and generation
of regional association plots (Supplementary Fig. 6). KORA genotype data has
been reported previously with many GWAS and was used as-provided by the
consortium. We, therefore, do not repeat details here11.
DNA was extracted from 359 samples from QMDiab and genotyped by the
WCM-Q genomics core facility using the Illumina Omni 2.5 array (version 8).
High-quality genotype data of 2,338,671 variants was obtained for 353 samples;
data for six samples was excluded due to a low overall call rate (o90%).
Removal of duplicate variants left 2,327,362 variants. In all, 134,830 variants
were removed due to missing genotype data (PLINK option --geno 0.02),
leaving 2,192,532 variants. In all, 941,058 variants were removed due to minor
allele threshold (PLINK option --maf 0.05), leaving 1,251,474 variants. In all,
28,175 variants were removed due to violation of Hardy-Weinberg equilibrium
(PLINK option --hwe 1E-6), leaving 1,223,299 variants. Of these variants,
1,221,345 were autosomal variants. The total genotyping rate of these remaining
variants was 99.7%.
Proteomics measurements. For KORA, the SOMAscan platform was used to
quantify protein levels. It has been described in detail before5,10,61–65. Brieﬂy,
undepleted EDTA-plasma is diluted into three dilution bins (0.05, 1, 40%) and
incubated with bin-speciﬁc collections of bead-coupled SOMAmers in a 96-well
plate format. Subsequent to washing steps, bead-bound proteins are biotinylated
and complexes comprising biotinylated target proteins and ﬂuorescence-labelled
SOMAmers are photocleaved off the bead support and pooled. Following recapture
on streptavidin beads and further washing steps, SOMAmers are eluted and
quantiﬁed as a proxy to protein concentration by hybridization to custom arrays of
SOMAmer-complementary oligonucleotides. Based on standard samples included
on each plate, the resulting raw intensities are processed using a data analysis
work ﬂow including hybridization normalization, median signal normalization
and signal calibration to control for inter-plate differences. One-thousand blood
samples from the KORA F4 study were sent to SomaLogic Inc. (Boulder Colorado,
USA) for analysis. Two of the shipped samples were incorrectly pulled from the
bio-bank and had no corresponding genotype data, one sample failed SOMAscan
QC, leaving a total of 997 samples from 483 males and 514 females for analysis.
Data for 1,129 SOMAmer probes (SOMAscan assay V3.2) was obtained for these
samples. Five of the probes failed SOMAscan QC, leaving a total of 1,124 probes for
analysis (Supplementary Table 1).
Three-hundred and ﬁfty-two samples from QMDiab were analysed at the
WCM-Q proteomics core, 338 of which overlapped with samples that were
also genotyped. No samples were excluded. Protocols and instrumentation were
provided and certiﬁed using reference samples by SomaLogic Inc. Experiments
were conducted under supervision of SomaLogic personnel. No samples or probe
data was excluded.
GWAS discovery study. We used PLINK (version 1.90b3w, Shaun Purcell,
Christopher Chang, https://www.cog-genomics.org/plink2) (ref. 66) to ﬁt linear
models to inverse-normalized probe levels, using age, gender and body mass index
as covariates. R version 3.1.3 (R: A language and environment for statistical
computing, R Foundation for Statistical Computing, Vienna, Austria, 2015,
http://www.R-project.org/) was used for data organization, plotting and additional
statistical analyses outside of the actual GWAS, including computation of linear
regression models based on raw and log-scaled data. We retained all SNP-probe
associations with uncorrected P values of a linear regression with genotypeo10 5
(14,647 associations covering 3,169 unique SNPs and 1,118 unique probes,
Supplementary Data 1, see Supplementary Fig. 7 for a Manhattan plot with all
associations). Genomic inﬂation was low (mean¼ 1.0035, max¼ 1.0251). There-
fore no correction for genomic control was applied. To deﬁne genetically inde-
pendent association loci, we lumped in a ﬁrst step for every given probe all
associations with correlated SNPs (linkage disequilibrium r240.1, window size
10Mb) and retrieved the SNP that had the strongest association at the sentinel for
this probe association. We then grouped all highly correlated sentinel SNPs
(linkage disequilibrium r240.9, window size 10Mb) into single loci. We report
uncorrected association P values from linear regression throughout this paper. In
all statistical analyses, we require a nominal signiﬁcance level of 0.05 (alpha error
5%). Multiple hypotheses testing is accounted for by using conservative Bonferroni
correction of the signiﬁcance level, based on the number of tested SNPs (509,946)
and probes (1,124), resulting in a genome- and proteome-wide signiﬁcance level of
Po8.72 10 11 (0.05/509,946/1,124). Four-hundred and ﬁfty-one loci had at
least one Bonferroni signiﬁcant sentinel association. For each of these 451 loci, we
also considered all probe associations with that same SNP at a signiﬁcance level of
Po9.86 10 8 (0.05/451/1,124) as Bonferroni signiﬁcant. This resulted in a total
of 539 genetic association signals (284 unique probes), each represented by a
sentinel SNP and one or more sentinel probes, including 391 cis-associations
(deﬁned by a SNP closer than 10Mb from the gene boundaries, 202 unique probes,
18.5% of all 1,090 autosomal probes) and 148 trans-associations (96 unique probes,
8.5% of all 1,124 probes). Box-whisker plots and association statistics using alter-
native data scaling methods (raw, log-normal, inverse-normal) are provided as
Supplementary Fig. 8. Annotations of the genetic loci using the SNiPA web-server
are provided as Supplementary Fig. 9. Regional association plots are in
Supplementary Fig. 6.
Replication. Using the QMDiab proteomics data as dependent variables, linear
regression models were ﬁtted using PLINK (version 1.90, version b3w), with age,
sex, body mass index, diabetes state, the ﬁrst three principal components of the
genotype data and the ﬁrst three principal components of the proteomics data as
covariates. The ﬁrst three genetic principal components separate the three major
ethnicities and the three proteomics principal components account for variability
introduced by a low degree of cell haemolysis. Genomic inﬂation was low
(mean¼ 1.020, max¼ 1.116). Therefore, no correction for genomic inﬂation was
applied. A tag SNP for replication of each of the 451 Bonferroni signiﬁcant loci
was selected by using the strongest association among all imputed SNPs in the
discovery study which had a correlation of r240.8 with the sentinel SNP. In all,
387 tag SNPs for the 451 originally identiﬁed SNPs could be identiﬁed for
replication, covering 462 SNP-probe pairs out of the originally identiﬁed
539 SNP-probe pairs. To consider an association as replicated, we, therefore,
required Po1.08 10 4 (0.05/462). 234 (50.6%) of the 462 attempted replications
fully replicated at a Bonferroni level of signiﬁcance (Po0.05/462), 384 (83.1%)
displayed nominal signiﬁcance (Po0.05). Out of 84 non-replicated associations
that were nominally signiﬁcant and that had a MAFo30% in both cohorts, only
one association displayed a discordant trend. We estimated the statistical power for
the replication by sampling: For each association we randomly selected without
replacement 338 individuals from the KORA cohort and computed the P value for
a linear regression with genotype on that subset. We repeated this 100 times and
report the 5th largest P value from this empirical distribution as the P value that
can be expected to be obtained with 95% power (p95). Based on this analysis, we
found that 208 SNP-probe pairs with a suitable tag SNP in QMDiab had 95%
replication power (p95o1.08 10 4). 171 of these 208 (82.2%) fully replicated in
QMDiab, 198 (95.2%) displayed at least nominal signiﬁcance.
Replication of previous SOMAscan based cis-associations. Using
the SOMAscan platform on 100 samples, Lourdusamy et al.5 reported
60 cis-associations at a false discovery rate of 5%. Forty-eight of these associations
had a suitable tag SNP in the genotyped KORA data set (r240.5) or association
data on an imputed SNP that allowed for replication. Thirty-four of these
SNPs were replicated (Po0.05/120, conservatively accounting for replication
attempts on tagged and imputed SNPs). The ﬁrst non-replicated association had
rank 21 (Supplementary Table 3).
Replication of immunoassay based cis-associations. Kim et al.7 reported
28 cis-associations for 27 analytes in the ADNI cohort using plasma proteomic data
by multiplex immunoassay on the Myriad Rules Based Medicine (RBM) Human
DiscoveryMAP panel v1.0 on the Lumine 100 platform. Out of 17 associations
that had overlapping probes, thirteen were replicated (Po0.05/17) (Supplementary
Table 4). Melzer et al.4 tested 40 protein levels determined by immunoassay and
reported 8 pQTLs. We replicated their second strongest association with IL6R.
Their strongest association is at the ABO locus with TNFa. However, TNFa is not
on the SOMAscan panel. We also found numerous other strong associations at the
ABO locus. Two weak associations of Melzer et al. (SHBG and CRP) were not
signiﬁcant in our study. The remaining associations from Melzer et al. were not
targeted by our panel. Enroth et al.9 used a multiplexed immunoassay and reported
23 cis-pQTLs. Two of the proteins (four associations) targeted by their assay were
not covered by our panel (VEGF-D, Ep-CAM) and one was located on the
X-chromosome and not tested for cis-association here (CD40-L). Of the remaining
18 cis-pQTLs, twelve associations were replicated (Po0.05/18) (Supplementary
Table 5).
Replication of MS-based cis-associations. Johansson6 reported ﬁve associations
and we found cis-pQTLs for four of them (Haptoglobin (HP), Alpha-1-antitrypsin
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(SERPINA1), Alpha-2-HS-glycoprotein, and APOE isoform 2). We did not,
however, ﬁnd a cis-pQTL for Complement C3 (C3), despite the fact that several
isoforms were targeted by our panel. Liu et al.8 reported 13 statistically signiﬁcant
association of MS-derived protein levels. Four of their proteins (FCN2, ITIH4,
KNG1, PON1) were targeted by our panel, and for two of them we found
a cis-pQTL in our study (KNG1, FCN2). Wu et al.53 reported protein associations
using MS in lymphoblastoid cell lines. However, this study was targeting
intracellular proteins and had no overlap with blood circulating proteins targeted
by our panel and could, therefore, not be used for replication.
Proteome annotation. We used SOMAmer probe identiﬁers as primary protein
identiﬁers (Supplementary Table 1). Some SOMAmer targets map to multiple
Uniprot identiﬁers (N¼ 41). They either refer to protein complexes (N¼ 32)
that are encoded at multiple genome loci, or to different variants of a same
protein encoded at a single gene locus (N¼ 9). In all, 1,090 SOMAmer targets
were encoded on autosomal chromosomes, 30 targets were encoded on the
X-chromosome, and four targeted viral proteins. Genome positions for all
SOMAmer targets were retrieved from Ensembl (http://www.ensembl.org) using
probe-speciﬁc Uniprot identiﬁers provided by SomaLogic. We used Ingenuity
Pathway Analysis (IPA) (http://www.ingenuity.com/products/ipa) to retrieve
additional information related to each probe. IPA provides a rich expert-curated
knowledgebase of literature-based protein-related information and requires unique
mapping to protein identiﬁers. Forty-one probes were present that target proteins
with multiple Uniprot IDs, and these were excluded from the IPA analysis.
A further 29 probes were excluded because multiple probes target a same protein.
Eight Uniprot IDs could not be mapped by IPA (LAG-1, LD78-beta, NKG2D,
HSP 70, and four viral proteins). Ultimately, 1,045 probes with unique Uniprot
IDs remained for the IPA annotation.
Functional annotation of the associations. We used the SNiPA server
(v3.1, http://snipa.org) to annotate 435 out of our 451 lead SNPs (Supplementary
Fig. 9). Sixteen SNPs were not available in the SNiPA database (poly-allelic variants
are currently excluded). SNiPA provides annotations for all SNPs that are in
linkage disequilibrium (R240.8) with and no more than 500 kb distant from
a sentinel SNP using genome assembly data based on GRCh37.p13, Ensembl
version 82, 1000-Genomes (phase 3, version 5) data, and GTEx (release 4) eQTL
associations for 13 tissues (see columns SNIPA_... in Supplementary Data 1).
SNiPA also provides primary effect predictions using the Ensembl VEP tool67 and
all GWAS association data from the GWAS catalogue68, metabotype associations
(http://gwas.eu) and dbGaP (columns GWAS_TRAITS, mGWAS_TRAITS,
dbGaP_TRAITS, accessed October 2015). Updates can be retrieved online at
http://snipa.org using the block-annotation tool.
Methylation GWAS. Data was downloaded from the BIOS QTL browser69
http://genenetwork.nl/biosqtlbrowser (accessed 9 Feb. 2016). Tagging SNPs
(r240.8) were identiﬁed using SNP–SNP correlations from KORA imputed
genotypes and meQTLs with BIOS-P valueso10 9 were retrieved.
Metabolomics GWAS. GWAS associations with mQTLs were obtained using
the GWAS-server (http://gwas.eu). This web-server provides access to raw
association data from the studies by Suhre et al.1, Shin et al.20 and Rafﬂer et al.70.
Extracted associations were limited to mQTL-P valueso10 8 and further
requiring P-gain4104 for ratios44 (Supplementary Table 8).
Disease GWAS lookup. We used SNiPA to identify overlapping disease-GWAS
entries. We further downloaded publically available association data for 70 clini-
cally relevant traits from the web-sites of 14 large disease GWAS consortia, based
on a list of available GWAS, and downloaded from https://www.med.unc.edu/pgc/
downloads. Supplementary Data 4 provides a list with links to all downloaded ﬁles
and the corresponding publications.
QMDiab total plasma N-glycosylation. Unthawed aliquots of identical samples
as for the proteome analysis were sent to Genos Ltd. (Zagreb, Croatia) for analysis
using ultra-performance liquid chromatography and liquid chromatography mass
spectrometry glycoproﬁling as follows: Total plasma N-glycan release and labelling.
Glycans were released from total plasma proteins and labelled as described
previously71. Brieﬂy, 10ml plasma sample was denatured with the addition of
20ml 2% (w/v) SDS (Invitrogen, USA) and N-glycans were released with the
addition of 1.2 U of PNGase F (Promega, USA). The released N-glycans were
labelled with 2-aminobenzamide (Sigma-Aldrich, USA). Free label and reducing
agent were removed from the samples using hydrophilic interaction liquid
chromatography solid-phase extraction. 0.2 mm 96-well hydrophilic polypropylene
ﬁlter-plate (GH Polypro, Pall Corporation, USA) was used as stationary phase.
Samples were loaded into the wells and after a short incubation washed 5 with
cold 90% acetonitrile (ACN). Glycans were eluted with 2 90ml of ultrapure water
after 15min shaking at room temperature, and combined eluates were stored at –
20 C until use. Total plasma N-glycome UPLC analysis. Total plasma N-glycans
were analysed by hydrophilic interaction ultra-performance liquid chromatography
(HILIC-UPLC) as described previously71. Brieﬂy, ﬂuorescently labelled N-glycans
were separated on an Acquity UPLC instrument (Waters, USA) using excitation
and emission wavelengths of 250 and 428 nm, respectively. Labelled N-glycans were
separated on a Waters BEH Glycan chromatography column, 150 2.1mm i.d.,
1.7 mm BEH particles, with 100mM ammonium formate, pH 4.4, as solvent A and
acetonitrile (ACN) (Fluka, USA) as solvent B. The separation method used a linear
gradient of 30-47% solvent A at ﬂow rate of 0.56mlmin 1 in a 23min analytical
run (Supplementary Fig. 10).
mRNA sequencing and allele speciﬁc transcription analysis. Lappalainen
et al.72 report mRNA sequencing of 462 lymphoblastoid cell lines of the
1,000 Genomes Project. RNA sequencing data was downloaded from EBI
(http://www.ebi.ac.uk/Tools/geuvadis-das/). Analysis was limited to 373 samples of
European ancestry. We used CLCBio genomics workbench (Qiagen Inc.) to align
reads, calculate RKPM (Reads Per Kilobase of transcript per Million mapped reads)
values and analyse the data.
Gaussian Graphical Network (GGM) construction. Using raw (unscaled)
data, regressing out ageþ genderþ bmi (997 samples with data for 1,124 variables)
we computed a GGM using the ggm.estimate.pcor function from the
R GeneNet package. The estimated optimal shrinkage intensity lambda
(correlation matrix) was 0.187. We obtained 3,943 GGM edges connecting
1,092 protein nodes with Bonferroni signiﬁcant partial correlation coefﬁcients
(Po 7.9 10 8¼ 0.05/(1,124*1,123/2)), provided as Supplementary Data 3. We
added SNP-probe association edges connecting 451 genetic loci to 539 proteins. We
further added SNP-disease association edges using all associations reported in the
GWAS catalogue (identiﬁed using SNiPA at linkage disequilibrium r240.8). We
also added all SNP-disease associations from 84 clinically relevant traits of 14 large
GWAS consortia that had a GWAS-P value Po10 8. These SNP-disease
edges were further manually curated to ascertain unique SNP-disease pairs.
SNP association to disease-related protein levels were excluded.
Data availability. All summary statistics and association data are freely available
(Supplementary Data 5), accessible online on an integrated web-server at
http://proteomics.gwas.eu. A fully functional docker-based version of the web-server
can also be freely downloaded from this link for local installation and network-free
usage (HTML5-based, no extra software is required). The informed consent given by
the study participants does not cover posting of participant level phenotype and
genotype data in public databases. However, data for KORA are available upon
request from KORA-gen (http://epi.helmholtz-muenchen.de/kora-gen). Requests are
submitted online and are subject to approval by the KORA board.
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